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Abstract
Genome wide association studies (GWAS) have been used to search for associations between genetic variants and
a phenotypic trait of interest. New technologies, such as next-generation sequencing, hold the potential to
revolutionize GWAS. However, millions of polymorphisms are identified with next-generation sequencing
technology. Consequently, researchers must be careful when performing such a large number of statistical tests,
and corrections are typically made to account for multiple testing. Additionally, for typical GWAS, the p value cutoff
is set quite low (approximately <10−8). As a result of this p value stringency, it is likely that there are many true
associations that do not meet this threshold. To account for this we have incorporated a priori biological
knowledge to help identify true associations that may not have reached statistical significance. We propose the
application of a pipelined series of statistical and bioinformatic methods, to enable the assessment of the
association of genetic polymorphisms with a disease phenotype–here, hypertension–as well as the identification of
statistically significant pathways of genes that may play a role in the disease process.
Background
Genome wide association studies (GWAS) can be used to
find associations between genetic variants and a phenoty-
pic trait of interest. New technologies, such as next-
generation sequencing, are promising to have a significant
impact on our ability to find disease associations through
GWAS. However, next-generation sequencing technology
currently is capable of identifying millions of polymorph-
isms in an individual genome. Therefore, when searching
for an association between a genetic polymorphism and
phenotypic trait, many statistical tests are performed.
Researchers must be careful when performing such a large
number of statistical tests, and corrections are typically
made to account for the multiple testing. Additionally, for
typical GWAS the p value cutoff is set quite low (approxi-
mately <10−8). As a result of this p value stringency, it is
likely that there are many true associations that do not
meet this threshold. To account for this, newer studies
have incorporated a priori biological knowledge to identify
true associations that may not have reached statistical sig-
nificance in light of the adjustment for the many statistical
tests.
The work described herein is based on the Genetic
Analysis Workshop 18 (GAW18). The GAW18 study is a
family-based study drawn from 2 cohorts participating in
the Type 2 Diabetes Genetic Exploration by Next-
Generation Sequencing in Ethnic Samples Consortium,
the San Antonio Family Heart Study, and the San Anto-
nio Diabetes/Gallbladder Study [1]. Participants with eli-
gible phenotype and genotype information came from 20
pedigrees. Individuals were enrolled from 1992 to 2003
and provided blood pressure, age, smoking status, and
blood pressure medication status at 1 to 4 visits over the
study time. The goal of our study was to identify genetic
associations with hypertension phenotypes based on the
data provided on the GAW18 organizing committee.
* Correspondence: jsedwards@salud.unm.edu
1Molecular Genetics and Microbiology, and Chemical and Nuclear
Engineering, 1 University of New Mexico, University of New Mexico Cancer
Center, Albuquerque, NM 87131, USA
Full list of author information is available at the end of the article
Edwards et al. BMC Proceedings 2014, 8(Suppl 1):S104
http://www.biomedcentral.com/1753-6561/8/S1/S104
© 2014 Edwards et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The hypertension phenotype has been investigated with
GWAS in the past [2-5], and it has long been believed that
hypertension is at least partially controlled through a
genetic component [6]. However, the genetic association
with hypertension is likely very complex, with the potential
for multiple competing effects and pathways, involving
renal salt processing, vascular constriction, etc [7]. The
first set of studies identified a number of interesting loci
[2,3]. In the Welcome Trust GWAS of hypertension, 2000
cases and 3000 controls were analyzed, and in the
Framingham Heart Study 1327 individuals had blood pres-
sure measurements performed longitudinally. No obvious
associations were identified, but a number of single-
nucleotide variants (SNVs) of interest were defined.
A subsequent directed analysis was able to confirm an
association between a single SNV and hypertension
(rs1937506). Interestingly, this SNV has opposite effects
in Americans of European origin versus Americans of
Hispanic origin [8]. Additionally, more recent GWAS of
hypertension in European and Amish populations have
identified SNVs that are statistically significantly associated
with hypertension [9,10].
In this study, we propose the use of a pipelined series
of methods to enable the assessment of the association of
genetic polymorphisms with hypertension, as well as to
identify the pathways of genes that may play a role in this
disease. To perform our analysis, we first removed poly-
morphisms from the analysis that were not within or
near (± 1 kilobase [kb]) exons. Then we performed a
family-based association analysis between the genotypes
and 5 hypertension-related phenotypes while correcting
for potential confounding factors (ie, age, sex, smoking,
hypertension medication). Lists of genes that were most
likely related to hypertension were identified and path-
way analysis was performed on these gene lists.
Methods
Cohort
The GAW18 study is a family-based study drawn from 2
cohorts participating in the Type 2 Diabetes Genetic
Exploration by Next-Generation Sequencing in Ethnic
Samples Consortium, the San Antonio Family Heart
Study, and the San Antonio Diabetes/Gallbladder Study
[1]. Details of the GAW18 data set are available elsewhere
(see http://www.gaworkshop.org/gaw18/index.html).
Phenotypes and covariates
At each visit systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured, and information on
use of blood pressure medication, smoking status, and age
were also collected. We defined 5 phenotypes to allow
multiple avenues for assessing genetic components
involved with blood pressure: hypertension status, SBP,
DBP, average yearly change in SBP (SBP slope), and aver-
age yearly change in DBP (DBP slope).
Hypertension was defined as SBP >140 mm Hg, DBP
>90 mm Hg, or the individual reported taking blood
pressure medication. Because individuals had from 1 to 4
visits, the basic hypertension variable was obtained as
ever versus never hypertensive across all visits. Covariates
were obtained from the same visit, with the first eligible
visit used when multiple visits were eligible. For indivi-
duals who were never identified as hypertensive, the cov-
ariates from the final visit were used.
SBP and DBP values were available at most visits. If an
individual indicated taking blood pressure medication,
then a standard adjustment of 10 mm Hg and 5 mm Hg
for SBP and DBP, respectively, was added [11]. For ana-
lyses with a single blood pressure variable, the SBP and
DBP values from an individual’s first visit were used. To
assess blood pressure changes over time, the slope from a
linear regression of blood pressure as a function of time
was obtained for SBP and DBP for each participant, yield-
ing a simple summary measure of average change per year
for each individual.
Genotypes
We used the next-generation sequencing genotyping data
from the 483 Hispanic individuals provided by the
Genetic Analysis Workshop organizers and the imputed
genotypes from 961 individuals in 20 large pedigrees. We
used the genotype calls provided by the organizers for
the 959 individuals, which included more than 8 million
polymorphisms on the odd-numbered chromosomes.
This original set was filtered down to include only poly-
morphisms inside of exons or within 1 kb of an exon.
Additionally, because we performed a pathway analysis
with the genes that contained polymorphisms statistically
most likely to be associated with hypertension, only poly-
morphisms associated with a gene were applicable to our
analysis. Polymorphisms outside of genes were excluded
from the statistical analysis. We identified polymorph-
isms that were within or near exons based on the UCSC
RefSeq annotation GRCh_37. The filtering identified
849,517 polymorphisms for analysis. Standard screening
for Hardy-Weinberg equilibrium was not used, as both
the family-based nature of this study and admixed popu-
lations, such as this Hispanic population, may violate
Hardy-Weinberg equilibrium as a result of the admixture
process [12].
Statistical methods for the association analysis
The primary purpose of the association analysis was to
identify potentially important genes to inform the sub-
sequent pathway analysis. Thus, we used 5 phenotypes
to allow the assessment of different pathways for the
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development of hypertension and other features con-
cerning blood pressure. The individual SNVs were
assessed for association with the various phenotypes.
All standard genetic models were assessed, including
additive, dominant, recessive, and heterozygote advan-
tage. Logistic regression was used to assess the binary
traits, whereas linear regression was used for the quan-
titative traits (SBP, DBP, SBP slope, and DBP slope).
Standard adjustment variables, age, age2, and gender,
were included, along with smoking status [13]. All ana-
lyses took into account family structure and used the
enhanced extended pedigree analysis in Golden Helix
(Bozeman, MT). Standard Bonferroni adjustment for
multiple comparisons was not used, but because the
primary purpose of the association analysis is to inform
a pathway analysis, the ranking of variables on the
basis of p values is not affected. Data summaries, such
as slopes from linear regression, and covariate values
were obtained utilizing SAS version 9.3.
Pathway analysis methodology
Pathway analyses were performed using Ingenuity Path-
way Analysis (IPA) pathway analysis software (Ingenuity
Systems, Inc., Redwood City, CA, http://www.ingenuity.
com). Identified pathways were ranked in order of
increasing p value. The unadjusted pathway p values
were computed using the hypergeometric distribution
(probabilities computed without replacement), using a
right-tailed Fisher’s exact test to assess the significance
of a given pathway in relation to the input data set. The
p value computation takes into account the number of
input molecules, the size of the requested pathway, and
the total number of molecules from the IPA knowledge
base that could potentially be included in the pathway.
Connections between molecules in the reported path-
ways reflect experimentally validated evidence of pair-
wise interactions from the literature, as annotated in the
IPA knowledge base. Pathway p values (reported as
score = −log10[p value]) correspond to a level of confi-
dence that a given pathway and its molecular interac-
tions did not arise by chance, but instead correspond to
biologically meaningful relationships among the input
genes associated with the given phenotype. For example,
a pathway with a p value of 10−9 would have a 1 in 1
billion chance of arising purely by chance, if the input
molecules had been chosen randomly from the underly-
ing knowledge base.
For each set of SNVs significantly associated with a
phenotype, we derived the corresponding gene lists for
input to the IPA software by mapping SNVs to the
nearest gene. A series of cutoffs were applied in order
to explore the effects of varying numbers of genes and
p value thresholds. Each cutoff resulted in a separate
gene list and distinct pathway analyses.
Pathway analyses were performed so as to construct
the most parsimonious pathway for each set of genes,
up to a maximum of MIPA interacting molecules (pro-
teins, chemicals), and such that the maximum number
of genes from the input set is included in a given path-
way. In the results reported here, MIPA was chosen to
be either 70 or 140.
Results
Although the median age of participants at enrollment
was only 38 years, 40% were identified as hypertensive
(Table 1). Participants were more likely to be female
(57.9%) and 21.7% were current smokers at the time of
enrollment. The cross-sectional analysis included 841
people, with 634 with multiple visits and thus eligible
for the analysis of change in blood pressure. Average
annual change in SBP and DBP were 0.95 and 0.23 mm
Hg, respectively. Below we will first present results from
the family-based logistic regression and linear regression
models for the 5 phenotypes identified SNVs and, thus,
genes that appeared to be associated with the pheno-
types (Figure 1). We will then apply a pathway analysis
to these lists of genes to identify functional connections
between the most significantly associated genes.
SBP
We identified ten SNVs within genes with -log10(p value)
>4.5. Two of these SNVs were on chromosome 1 (1p34/
CLSPN), 3 on chromosome 7 (7q11/AUTS2), 2 on chro-
mosome 11 (11q23/HTR3B, 11q23/TMPRSS5), and 3 on
chromosome 13 (13q34/LAMP1). Interestingly, 2 of these
proteins are on the cell membrane (HTR3B, TMPRSS5)
and 1 is identified as an ion channel (HTR3B).
DBP
Six genomic regions were associated (-log10[p values]
>4.5) with the DBP quantitative trait. These regions are
Table 1 Summary information on demographic and
phenotypic variables
Demographic or phenotypic variable Summary measures
Information from first visit (n = 841)
Sex (% female) 57.9
Age (median [min, max]) in years 38 (16, 94)
Smoking status (% current smoker) 21.7
Taking blood pressure medication (%) 10.0
Phenotypes: cross-sectional (n = 841)
Ever hypertensive (%) 40.0
SBP (median [25th, 75th percentiles]) (mm Hg) 118 (110, 130)
DBP (median [25th, 75th percentiles]) (mm Hg) 72 (65, 78)
Phenotypes: average yearly change (n = 634)
SBP (mean [std]) (mm Hg) 0.95 (2.09)
DBP (mean [std]) (mm Hg) 0.23 (1.27)
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on chromosomes 1q, 3q, 5q, 9q, 17q, and 21q. The
chromosome 1 region is 1q24 and the SNVs are in the
C1orf114 and SLC19A2 genes. The SLC19A2 gene
encodes a protein that is annotated as a transporter and
it exists on the cell membrane. The chromosome 3
region with SNVs of potential significance is 3q25 and
the SNVs are within 3 adjacent genes (SMC4, IFT80,
and KPNA4). The chromosome 5 SNV is in FBN2
which lies on 5q23. There are 2 chromosome 9 SNVs,
both of which are in PRDM2 on 9q34. A single SNV of
potential significance exists on chromosome 17 (17q11)
and is in the NUFIP2 gene. And finally, the 3 SNVs on
chromosome 21 (21q22) are in the TRPM2 gene, which
is a transient receptor potential cation channel that is
involved in Ca++ and Na+ transport. It should be noted
that 6 of the top 7 SNVs (with functional annotations)
are transporters or ion channels.
SBP slope
From our family-based analysis, we identified 2 genomic
regions associated (-log10[p values] >4.5) with the SBP
slope quantitative phenotype, 3q13 and 9q32. The 3
SNVs on the chromosome 3 region were in the WDR52
gene, and 2 SNVs on 9q32 were in the SNX30 gene.
One of the most significant SNVs associated with a
change in SBP and of particular interest is VAV3
(p value = 3.97 × 10−5). This SNV was also identified as
a key gene in association with a change in DBP and it
has been implicated in hypertension and tachycardia in
a mouse model [14].
DBP slope
Five genomic regions were associated (-log10[p values]
>4.5) with the DBP slope quantitative phenotype, 1p36,
7p22, 9p21, 17p13, and 19q13. There are 6 SNVs on
Figure 1 Genome wide association scans for 5 different phenotypes related to hypertension. For each of the 5 phenotypes, the -log10 of
the p value associated with each SNV in (or near) the coding regions. Data from only odd-number chromosomes was provided as part of the
GAW18 project; consequently, there is no information for any of the even-number chromosomes, which appear as blank regions on the plots.
HTN, hypertension.
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chromosome 1 in the KIF1B gene. The chromosome 7
SNV is in the SDK1 gene. On chromosome 9 there are
13 SNVs in 3 adjacent genes that are potentially asso-
ciated with the phenotype. These SNVs are in the
SMU1, DNAJA1, and APTX genes. On chromosome 1
there is a single SNV with potential significance within
the PER1 gene. Finally, there is a single SNV in the
PEPD gene on chromosome 19.
Hypertension
We identified the most genomic regions associated
(-log10[p values] >4.5) with the hypertension binary phe-
notype. There were 11 regions: 1p36 (PTCHD2 and
C1orf187), 3p26 (IL5RA), 7q22 (GATS and STAG3),
7q31 (LMOD2 and WASL), 11q12 (OR8U1 and OR8U8),
15q15 (PLA2G4E), 15q25 (ADAMTSL3), 17p13
(PITPNM3), 17q25 (CCDC57), 19p13 (WDR18), and
19q13 (PPP6R1). Although none of these regions con-
tains a gene that has a known biological relationship with
hypertension, when the p value cutoff is increased, a
number of genes that are associated with hypertension
appear on this list. Furthermore, many of these poten-
tially interesting genes also appear on the other pheno-
type lists.
Genes associated with phenotype
The 5 phenotypes defined in this study were constructed
in an attempt to capture different manifestations and etiol-
ogies of hypertension. Consequently, the genes emerging
from the association analysis for each phenotype are
expected to display distinct biological patterns, in principle
traceable to different underlying patterns of disease and
pathway dysregulation. In addition, there is the possibility
of observing commonalities across phenotypes, global
patterns that transcend specific phenotypic definitions.
Several such patterns emerged from our analysis of the
gene lists for the various phenotypes.
In particular, of the 5 hypertension phenotypes consid-
ered, DBP and hypertension yielded the largest numbers
of significant genes (N = 34 and 38, respectively) with a
p value cutoff of 10−4. Genes with family annotations of
“ion channel” or “transporter” are notable because of the
fundamental importance of ion and salt transport pro-
cesses underlying hypertension pathways [15,16]. Exam-
ples of ion channel-annotated genes derived from the
DBP phenotype include TRPM2 (cation channel),
SCN11A (sodium ion channel), ITPR1 (Ca+2-release med-
iator), and, (implicated in hypertension [2,17]. RYR3 also
appears in the 5 phenotype intersection list, as does the
NALCN sodium leak channel. Cellular transporters are
present within several phenotypes, and of particular note,
they span 3 distinct molecular motor protein subfamilies:
KIF1B (kinesin; DBP slope); DNAH14 (dynein; SBP
slope), DNAH17, and DNAH9 (dynein; 5 phenotype
intersection); and MYO1D (myosin; 5 phenotype inter-
section). MYO1D has been associated with hypertension
[18], and phosphorylation of the myosin light chain,
mediated by Ca+2, is necessary for the regulation of vas-
cular small muscle contraction [19]. VAV3 was identified
in both the DBP slope and SBP slope phenotypes as
noted above.
Pathways associated with phenotypes
The 5-way intersection gene list reflecting genes com-
mon across all 5 phenotypes with a p value less than 0.01
(N = 116) and the most significant 40 genes (p <3.5 ×
10−5) derived from the union of the genes across all 5
phenotypes were subjected to pathway analysis. We
imported each phenotype gene list, as well as the top 40
list from the phenotype union, and the N = 116 intersec-
tion of top phenotype genes (Figure 2), into the IPA soft-
ware. Figure 3 illustrates 2 of the top-scoring pathways.
In these pathways, UBC (ubiquitin) and Ca+2 are promi-
nent hubs, even though these molecules were not
included in the input gene lists derived from the original
list of statistically significant SNVs. UBC, located on
(even-numbered) chromosome 12 (12q24.3) and thus not
directly accessible through data provided in this study,
appears as a hub in almost all pathways, while the cal-
cium divalent cation, required for smooth muscle con-
traction, appears in 2 of the statistically significant
pathways. VAV3, mentioned above, is a hub in the SBP
Figure 2 Venn diagram of top genes for each phenotype. A list
of all SNVs that had p values <0.01 was analyzed. All the genes in
these regions were tabulated and a Venn diagram was constructed
to identify which genes existed on each of the 5 different lists.
DDBP, change in DBP overtime; HTN, hypertension; DSBP, change in
SBP overtime
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slope pathway. Interestingly UBC controls the modula-
tion of cell surface receptors and ion channels [20], and
there is emerging evidence for its importance in the
initiation of atherosclerosis and the proliferation of cardi-
ovascular disease [21,22]. Although it is intriguing that
UBC appeared in nearly all of the statistically significant
pathways, it is clearly premature to attribute too much
significance to this finding in light of the incomplete nat-
ure of the source data set, and the wide range of cellular
processes affected by ubiquitin protein modification in
general.
Conclusions
In summary, we have demonstrated–in the context of the
GAW18 hypertension data set–a proposed methodology
for the unified analysis of next-generation sequence data.
This method used biostatistical methods for analyzing
GWAS to inform a pathway analysis. Our approach inte-
grates traditional GWAS-based statistical analysis in which
variants and clusters of variants are used to define specific
genetic disease markers, coupled with a broader systems
biology and pathway-based approach that can potentially
shed light on the diverse biological origins of complex dis-
eases such as hypertension. It is important to note that the
specific results reported here on the genetics of hyperten-
sion need to be reassessed with a more complete data set,
as the GAW18 data set included only odd-numbered
chromosomes, thus omitting half of the genes in the gen-
ome. Because pathway analyses utilize information for
every gene, either a positive association or none, this
major omission clearly impacted the analyses reported
here. That is, the omission of a gene as input to a pathway
analysis is effectively an assessment of its lack of impor-
tance. Because genes on even-numbered chromosomes
could not be assessed in this study, and the underlying
database of biological interactions is agnostic with respect
to input gene lists, the pathways that were most likely to
be identified were those with a preponderance of genes on
odd-numbered chromosomes. Even in studies where com-
plete information is available as input to an analysis, it is
important to appreciate that the results of pathway ana-
lyses are at best a starting point for further biological stu-
dies, as they are limited by biases and incomplete data in
the underlying knowledgebase. The possibility also exists
that one may identify a “significant molecule” that simply
reflects a pervasive underlying process, rather than one
that is truly important and of functional significance in the
context of a particular disease. Nevertheless, a number of
suggestive results emerged from our analyses that repre-
sent a promising starting point for future studies of hyper-
tension using expanded next-generation data sets and the
integrated computational methodology described here.
Figure 3 Pathways generated by lists of genes from the association analysis. A, Pathway analysis of top 40 statistically significant genes
(p <3.5 × 10−5) derived from the union of the genes across all 5 phenotypes, MIPA = 70. Pathway score = 77, corresponding to p = 10
−77. This
was the only statistically significant pathway obtained for this set of genes. Molecules in red correspond to genes (N = 30, 75%) from the input
list of 40. Functional annotations for this pathway include cell death and survival, gastrointestinal disease, and inflammatory disease. B, Pathway
analysis of the top 38 statistically significant genes (p <1.0 × 10−4) derived from the hypertension phenotype, MIPA = 70. Pathway score = 62,
corresponding to p = 10−62. This was the only statistically significant pathway obtained for this set of genes. Molecules in red correspond to
genes (N = 25, 66%) from the input list of 38. Functional annotations for this pathway include cellular assembly and organization, cellular function
and maintenance, and cell death and survival.
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